Less than two months after conducting its initial public offering, GTx Inc. found a potential dream deal for an early clinical program focused on selective androgen receptor modulators (SARMs). (BioWorld Today)

BioRexis Pharmaceutical Corp. attracted new and existing investors with its protein and peptide drug research, raising $30 million in an oversubscribed Series B round. (BioWorld Today)

Two companies focused on developing drugs for cancer and inflammation patients raised a combined $42 million this week in private funds. (BioWorld Today)

Breast cancer patients taking Abraxane in a Phase III trial responded almost twice as well as they did when taking a marketed product - providing American BioScience Inc. and American Pharmaceutical Partners Inc. (APP) the data they needed to file a new drug application. (BioWorld Today)

Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today)